1. Introduction {#sec1}
===============

The metabolic roles of peptide hormones with endocrine activity have received considerable attention in the context of the rising incidence of diabetes and obesity. Notably, multiple gut hormones secreted from enteroendocrine cells control islet function and glucose homeostasis, and a subset of these hormones also regulate food intake, body weight, and lipid metabolism [@bib1], [@bib2]. Furthermore, some members of the circulating fibroblast growth factor family, exemplified by fibroblast growth factor 21 (FGF-21), also exhibit hormone-like activity, and have been evaluated as therapeutic candidates for the treatment of diabetes, obesity, and non-alcoholic steatohepatitis [@bib3], [@bib4]. The favorable metabolic actions of several gut hormones, notably glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like-peptide-1 (GLP-1), have received considerable attention, and GLP-1 receptor agonists have been developed for the therapy of type 2 diabetes (T2D) and obesity [@bib5].

A conserved feature shared by many peptide hormones is their short biological half-life, reflecting extraction and degradation by peripheral organs, urinary clearance, as well as enzymatic inactivation. Notably, N-terminal peptide cleavage by dipeptidyl peptidase-4 (DPP-4), the most extensively studied member of the DPP-4 activity and/or structure homologue (DASH) proteins [@bib6], plays a critical role in terminating hormone action [@bib7]. DPP-4 cleaves and inactivates GLP-1, oxyntomodulin, pituitary adenylate cyclase-activating peptide (PACAP), and glucose-dependent insulinotropic polypeptide (GIP), highlighting its key role in control of glucose homeostasis [@bib8]. The biological importance of DPP-4 for control of islet function and glucose homeostasis has been demonstrated using mouse genetics, as well as through analysis of the biological activity of highly selective DPP-4 inhibitors in animals and humans [@bib7], [@bib9], [@bib10]. Notably, genetic elimination of *Dpp4* in mice improves glucose homeostasis via potentiation of gut hormone action [@bib11], [@bib12], findings mirrored by administration of small molecule highly selective DPP-4 inhibitors [@bib7], [@bib9], [@bib10].

The therapeutic success of DPP-4 inhibitors for the treatment of T2D has stimulated interest in the metabolic actions of structurally-related DASH enzymes [@bib6], [@bib7], including fibroblast activation protein (FAP)/seprase, a member of the DASH family with over 50% amino acid sequence identity with DPP-4 [@bib13]. Intriguingly, both DPP-4 and FAP were first studied as candidate regulators of tumor cell growth, with elevated FAP expression detected within activated stromal fibroblasts of human epithelial cancers [@bib14]. Both DPP-4 and FAP exhibit overlapping dipeptidyl peptidase activity and cleave a subset of similar substrates *ex vivo* [@bib15]. In contrast to DPP-4, FAP also has a unique endopeptidase activity with a Gly--Pro specificity [@bib16], [@bib17]. Furthermore, both DPP-4 and FAP exert activity as cell-anchored enzymes and via circulating soluble forms that retain enzyme activity [@bib18], [@bib19]. FAP enzymatic activity is detectable, albeit at relatively low levels, in metabolically active tissues such as muscle, pancreas, and adipose tissue [@bib19], [@bib20], [@bib21].

The observation that talabostat improves glucose homeostasis in mice was linked to FAP inhibition and potentiation of fibroblast growth factor-21 (FGF-21) activity [@bib22]. However, early on, talabostat had been shown to be a potent DPP4 inhibitor [@bib23] with glucose-lowering activity [@bib24], [@bib25]. In fact, talabostat is ∼20,000-fold more potent as an inhibitor of DPP-4 (Ki ∼ 5 pM) than of FAP (Ki ∼ 100 nM) [@bib26]. Hence, ascribing anti-diabetic activities of talabostat to the inhibition of FAP can only be done in the absence of or concomitant inhibition of DPP-4 activity.

The emerging metabolic importance of FAP, and its overlapping structural and functional relationship to DPP-4, prompted us to further assess the importance of endogenous FAP in the control of glucose and lipid homeostasis. We therefore examined the effects of a potent and specific FAP inhibitor, (S)-N-(2-(2-Cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-quinoline-4-carboxamide [@bib27] herein referred to as Compound 60 (CPD60), and found that it does indeed improve glucose tolerance, albeit modestly. In contrast, *Fap*^−/−^ mice did not exhibit improved glucose control, or resistance to weight gain after prolonged high fat feeding. Furthermore, talabostat\'s anti-diabetic activities were independent of FGF21 or FAP. Taken together, our findings indicate that murine FAP is not a critical determinant of islet function, glucose homeostasis, weight gain, and the metabolic response to high fat feeding in mice.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

All animal studies were carried out according to protocols approved by Sinai Health System and The Centre for Phenogenomics (TCP, Toronto, Ontario, Canada). For studies using C57BL/6J mice, male animals aged 12 weeks or older were obtained from the in-house breeding colony at TCP. All mice were housed under specific pathogen-free conditions in ventilated microisolator cages and maintained on a 12-h light/dark cycle with free access to food and water unless otherwise noted. To account for sexual dimorphism, both males and females were studied in parallel for most experiments.

### 2.1.1. *Fap*^−/−^*mice* {#sec2.1.1}

*Fap*^−/−^ (*Fap*^em1Tcp^/Ddr) mice on a C57BL/6J background were generated at TCP by embryonic pronuclear microinjection of Cas9 mRNA and a single guide RNA with a spacer sequence of CCACTAAAGCAAGCGCAGCC, which resulted in a 5 bp deletion (GCGCT) in exon 2 at approximate position 62,573,481 bp (GRCm38) (confirmed by Sanger sequencing). This mutation is predicted to cause amino acid sequence changes after residue 15 and early truncation 17 amino acids later. Genotyping was performed using the following primers: Primer Fap-F (5′→3′): TCAAAAGCTCTGTGGGGAA; Primer Fap-R (5′→3′): GGTTTGGAATAATAGGGGCATAG. These primers amplify a 931 bp product, which, following digestion with Mwo1 (N.E.B. product \#R0573S), yields a 794bp DNA fragment. In contrast, Mwo1 does not cleave a PCR product generated from homozygous knockout mouse DNA (see [Figure S1](#appsec1){ref-type="sec"}).

### 2.1.2. *Fgf21*^−/−^ mice {#sec2.1.2}

*Fgf21*^−/−^ (Fgf21^tm1.1Djm^; MGI:[4354163](mgi:4354163){#intref0010}) mice were re-derived at TCP after being obtained from the laboratory of Steven A. Kliewer and originally developed by David J. Mangelsdorf [@bib28]. Genotyping was performed using the following primers: Primer F21SeqF1 (5′→3′): CCTCCAGATTTAGGAGTGCAGA; Primer F21GREV6-1 (5′→3′): GAAGACAGCCAGCAGCAGTCG; Primer F21NeoRev3 (5′→3′): GCATCGCCTTCTATCGCCTTCTTG. Together, these primers amplify a 500bp band from DNA corresponding to a WT allele, and a 300bp band from DNA corresponding to a *Fgf21* mutant allele.

### 2.1.3. *Dpp4*^−/−^ mice {#sec2.1.3}

*Dpp4*^−/−^ (CD26^−/−^) mice were maintained in the Drucker lab and genotyped as described [@bib11], [@bib29].

2.2. Glucose, insulin, and lipid tolerance tests {#sec2.2}
------------------------------------------------

All tests were performed following a 5-hour daytime fast to minimize stress, with blood samples collected via tail-vein. For oral or intraperitoneal glucose tolerance tests (OGTT and IPGTT, respectively), 1.5 g/kg of glucose was given at Time 0. Insulin Tolerance Tests (ITT) were performed using a single IP dose of 0.7U/kg insulin (Humulin R, Eli Lilly) for lean RC-fed mice, or 1.2U/kg for HFD-fed mice. For Lipid Tolerance Tests (LTT), a 200 μL gavage of olive oil (Sigma) was administered and blood samples were collected for up to 180 min and assayed for non-esterified fatty acids (NEFAs) using NEFA-HR(2) (Wako) or triglycerides (TGs) using the Trig-GB kit (Roche). Blood samples were collected in K3-EDTA coated Microvette tubes (Sarstedt) (volume 50--100 μl) and, when measuring hormones at the indicated time points, mixed with 5--10 μl of a chilled solution containing 5000 kIU/ml Trasylol (Bayer), 32 mM EDTA, and 0.01 mM Diprotin A (Sigma) to prevent degradation. When applicable, drug pre-treatment using CPD60 or talabostat (Val-boroPro), acquired from the laboratory of Dr. William Bachovchin (Tufts University, Boston MA, USA) was performed by oral gavage 30--40 min prior to glucose treatments.

2.3. Hormone and enzymatic assays {#sec2.3}
---------------------------------

Plasma insulin levels were measured in 5 μL volumes using the Ultrasensitive Mouse Insulin ELISA (Alpco Diagnostics). Plasma glucagon was measured using a 10 μL Glucagon ELISA (Mercodia). Fasting FGF-21 was measured from a single tail-vein bleed following an 18 h fast using the Rat/Mouse FGF 21 ELISA Kit (Millipore). For analysis of FAP activity, 3144-AMC was used as a FAP-specific fluorogenic substrate [@bib19] (obtained from Dr. William Bachovchin, Tufts University), along with a reference AMC curve ranging from 0 to 50 μM. A 1:60 dilution of plasma in PBS was combined with 50uM 3144-AMC, shaken, and incubated at 37 °C with measurements (Ex. 360mn/Em. 460 nm) taken every 5 min over a 1 h time course in a temperature controlled EnSpire 2300 multilabel plate reader (PerkinElmer). For tissue FAP activity assays, ∼80--120 mg of each tissue was homogenized using TissueLyser II with stainless steel bead agitation in a buffer containing 1 mM EDTA, 10% w/v glycerol, 0.02% Brij-35, 50 mM Tris--HCl, pH 8. The resulting homogenate was diluted 1:10 in PBS and assayed as above. This protocol was adapted from [@bib19]. For plasma DPP-4 activity, H-Gly-Pro-AMC HBr (Bachem \#I-1225) was used as a substrate and plasma samples assayed in a 20-minute room-temperature timed protocol as described previously [@bib30]. A single dose of CPD60 (20 mg/kg) produced sustained (more than 75%) inhibition of FAP activity for at least 12 h ([Figure 1](#fig1){ref-type="fig"}A and unpublished observations).Figure 1**Pharmacological inhibition of FAP improves glucose homeostasis without affecting plasma levels of insulin or glucagon.** CPD60 was given by oral gavage and FAP and DPP-4 activity were measured in 16-week old male C57BL/6J mice. Then, the mice were placed on a HFD for 2--3 weeks and given the indicated doses of either CPD60 or vehicle (PBS) by oral gavage 30 min prior to each test. **A)** Plasma FAP activity following CPD60 treatment. **B)** Plasma DPP-4 activity following CPD60 treatment. **C)** Oral glucose tolerance test (OGTT) at various doses of CPD60 and area under curve analysis (AUC) (right). **D)** Intraperitoneal Glucose Tolerance Test (IPGTT) and AUC. **E)** Insulin levels during OGTT. **F)** Glucagon levels during OGTT. **G)** Insulin Tolerance Test (ITT) and AUC. **H)** Triglycerides (TGs) and AUC during a Lipid Tolerance Test (LTT). Results were analyzed using ANOVA (Panels C and D), Two-way ANOVA (Panels E and F) or two-tailed *t*-test (Panels G and H). \*P \< 0.05.Figure 1

2.4. Magnetic resonance imaging (MRI), indirect calorimetry, and locomotor activity {#sec2.4}
-----------------------------------------------------------------------------------

For assessment of body composition, a whole body magnetic resonance analyzer was used (EchoMRI-100, Echo Medical Systems). Measures of O~2~ consumption, CO~2~ production, respiratory quotient, heat production, and physical activity were obtained after 2 days of acclimatization and 1 day of measurement using a Rodent Oxymax system (Columbus Instruments). Food intake was obtained manually by weighing food before and after 3 days in metabolic cages.

2.5. Gene expression analysis {#sec2.5}
-----------------------------

RNA was isolated from various tissues according to the manufacturer\'s protocol (Tri-Reagent, Molecular Research Center Inc., Cincinnati, OH). Homogenization was performed in a medium-throughput manner using the TissueLyser II (Quiagen) with stainless steel beads. First-strand cDNA was synthesized using SuperScript III reverse transcriptase (Invitrogen) and random hexamers. Quantitative polymerase chain reaction (qPCR) was performed using the QuantStudio 5 Real-Time PCR System (ThermoFisher) and TaqMan Gene Expression Assays and Universal PCR Master Mix (Applied Biosystems) using the following TaqMan primers: *Fap* (Mm01329177_m1), *Dpp4* (Mm00494538_m1), *Dpp8* (Mm01151441_m1), *Dpp9* (Mm00841122_m1), *Fgf21* (Mm00840165_g1).

2.6. Histological analysis {#sec2.6}
--------------------------

Following animal sacrifice, liver and pancreata were isolated and then formalin-fixed and paraffin embedded, sliced at 4 μm thickness, and slide-mounted. H&E staining of livers and immunostaining of insulin and glucagon in pancreata, as well as slide scanning (ScanScopeCS System, Aperio Technologies) was performed by the Pathology Services facility at the Lunenfeld-Tanenbaum Research Institute. Quantification of α-cell and β-cell area was performed using positive pixel count analysis on Aperio ImageScope Viewer software (Leica Biosystems), with weak positive pixels discounted to minimize the effects of non-specific staining.

2.7. Data analysis {#sec2.7}
------------------

All data were graphed and analyzed using GraphPad Prism, version 7.0d. Data are presented as mean +/− SD. Analyses performed included non-linear regression, ANOVA, 2-way ANOVA, two-tailed *t*-test, and paired *t*-test where appropriate. A *P* value less than 0.05 was considered to be statistically significant.

3. Results {#sec3}
==========

3.1. Pharmacological FAP inhibition improves glucose tolerance {#sec3.1}
--------------------------------------------------------------

To study the effects of acute FAP inhibition on glucose tolerance, we used a relatively selective FAP inhibitor *(S)-N-(2-(2-Cyano-4,4-difluoropyrrolidin-*1-yl*)-2-oxoethyl)- quinoline-4-carboxamide*, CPD60 [@bib27], [@bib31], previously demonstrated to completely suppress FAP activity in mouse plasma [@bib32]. When administered orally, CPD60 robustly inhibited plasma FAP enzymatic activity as early as 15 min post-gavage ([Figure 1](#fig1){ref-type="fig"}A). In contrast, the same doses of CPD60 had no effect on plasma DPP-4 activity ([Figure 1](#fig1){ref-type="fig"}B). Nevertheless, despite marked inhibition of FAP activity, CPD60 only modestly reduced glycemic excursion during oral and intraperitoneal glucose tolerance tests in a dose-dependent manner ([Figure 1](#fig1){ref-type="fig"}C--D), without concomitant changes in plasma levels of insulin and glucagon. Insulin sensitivity approximated by insulin tolerance testing was not different following administration of CPD60 ([Figure 1](#fig1){ref-type="fig"}E--G). Moreover, plasma triglycerides assessed following olive oil gavage were not different in the presence or absence of CPD60 ([Figure 1](#fig1){ref-type="fig"}H).

3.2. *Fap*^−/−^ mice have reduced plasma and tissue FAP activity {#sec3.2}
----------------------------------------------------------------

To determine the importance of endogenous FAP activity for metabolic homeostasis independent of chemical enzyme inhibition, we used CRISPR/Cas9-mediated mutagenesis to generate *Fap*^−/−^ mice on a C57BL/6J genetic background. A 5 base-pair deletion in exon 2 was predicted to produce a truncated non-functional FAP protein ([Figure 2](#fig2){ref-type="fig"}A). Indeed, we observed complete loss of plasma FAP activity in *Fap*^−/−^ mice, with an intermediate reduction of plasma FAP activity in *Fap*^+/−^ mice ([Figure 2](#fig2){ref-type="fig"}B, C). Furthermore, tissue FAP activity was markedly reduced or undetectable in pancreas, liver, muscle and adipose tissue of regular chow (RC)- or high fat diet (HFD)-fed *Fap*^−/−^ mice ([Figure 2](#fig2){ref-type="fig"}D). Taken together, these findings substantiate the functional elimination of circulating and tissue FAP enzymatic activity in *Fap*^−/−^ mice.Figure 2**Generation and characterization of *Fap*^−/−^ mice.A)** A map of the FAP gene in mice and the partial cDNA sequence of wild-type and mutant *Fap* alleles are shown. The mutation causes a 5bp deletion and frame-shift occurring in exon 2 that is predicted to cause amino acid changes after Ala15 and an early truncation of the protein 17 amino acids later in exon 3. Start codon is in green; stop codons are in red. Black line indicates sequence targeted by guide RNA. ˆ indicates a new exon. **B)** AMC appearance over time during FAP activity assay in *Fap*^+/+^, ^+/−^, ^−/−^ mice. **C)** Average FAP activity (slope analysis) over duration of FAP activity assay. **D)** FAP activity in various tissues from *Fap*^+/+^. Statistical significance was determined with ANOVA. \*P \< 0.05, \*\*\*P \< 0.001, \*\*\*\*P \< 0.0001, when compared to corresponding *Fap*^+/+^ control groups.Figure 2

3.3. *Fap*^−/−^ mice do not exhibit abnormalities in body weight or glucose homeostasis {#sec3.3}
---------------------------------------------------------------------------------------

FAP substrates include neuropeptides and metabolically active hormones such as FGF-21, known to regulate islet function, insulin sensitivity, and body weight [@bib15], [@bib22]. Accordingly, we assessed metabolic homeostasis in RC-fed *Fap*^−/−^ mice ([Figure S2](#appsec1){ref-type="sec"}). Body weight and body composition were not different in male ([Figure 3](#fig3){ref-type="fig"}A--B) and female ([Figure S3A,B](#appsec1){ref-type="sec"}) *Fap*^+/+^ vs. *Fap*^−/−^ mice; daily food intake was modestly reduced in male ([Figure 3](#fig3){ref-type="fig"}C) but not in female *Fap*^−/−^ mice ([Figure S3C](#appsec1){ref-type="sec"}). Moreover, male *Fap*^−/−^ mice did not exhibit differences in oral or intraperitoneal glucose tolerance, insulin sensitivity, nor changes in corresponding levels of insulin or glucagon in the fasting state, or during glucose or insulin challenge ([Figure 3](#fig3){ref-type="fig"}D--L). Glucose tolerance and insulin sensitivity were also comparable in *Fap*^+/+^ vs. *Fap*^−/−^ female mice ([Figure S3](#appsec1){ref-type="sec"}D--G). Furthermore, plasma triglyceride levels measured following olive oil gavage did not differ in *Fap*^+/+^ vs. *Fap*^−/−^ mice ([Figure 3](#fig3){ref-type="fig"}M). Metabolic parameters including VO~2~, VCO~2~, respiratory exchange ratio (RER), heat production, and locomotor activity were not different in male or female *Fap*^+/+^ vs. *Fap*^−/−^ ([Figure S4](#appsec1){ref-type="sec"}). Hence, in the absence of a superimposed metabolic stress such as a high fat diet, germline loss of FAP is not associated with impaired regulation of glucose or energy homeostasis in RC-fed mice up to 40 weeks of age.Figure 3**Male *Fap***^**−/−**^**mice fed normal rodent chow exhibit normal body weight, glucose and lipid tolerance.** Adult male *Fap*^+/+^ and ^−/−^ mice were provided with RC and subjected to weekly metabolic tests beginning at 24 weeks of age. **A)** Body weight. **B)** Body composition. **C)** Average 24-hour food intake. **D)** OGTT and AUC analysis. **E)** Plasma insulin during OGTT. **F)** Plasma glucagon during OGTT. **G)** IPGTT and AUC analysis. **H)** Plasma insulin during IPGTT. **I)** Plasma glucagon during IPGTT. **J)** ITT and AUC analysis. **K)** Fasting plasma insulin prior to ITT. **L)** Plasma glucagon during ITT. **M)** TG levels during LTT and AUC analysis. Data were analyzed using 2-way ANOVA or two-tailed *t*-test. \*P \< 0.05.Figure 3

3.4. *Fap*^−/−^ mice are not protected from obesity and hyperglycemia after high fat diet feeding {#sec3.4}
-------------------------------------------------------------------------------------------------

Given the lack of metabolic phenotypes in RC-fed *Fap*^−/−^ mice, we studied male and female *Fap*^−/−^ mice after several months of HFD feeding ([Figure S2](#appsec1){ref-type="sec"}). No differences in body weight or body composition were detected after 22 wks of HFD feeding, although food intake was reduced in male, but not in female *Fap*^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}A--C, [Figure S5](#appsec1){ref-type="sec"}A-C). Moreover, oral and intraperitoneal glucose tolerance, insulin sensitivity, and plasma levels of insulin and glucagon were not different either in the fasted state, or when assessed after glucose administration, in HFD-fed *Fap*^+/+^ vs. *Fap*^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}D--L, [Figure S5](#appsec1){ref-type="sec"}D-F). Similarly, plasma triglycerides were not different following olive oil gavage in *Fap*^+/+^ vs. *Fap*^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}M, [Figure S5](#appsec1){ref-type="sec"}G). Furthermore, respiratory rates, RER, and locomotor activity were similar in male and female *Fap*^+/+^ vs. *Fap*^−/−^ mice ([Figure S6](#appsec1){ref-type="sec"}). Consistent with the observations of unchanged glucose tolerance and lipid tolerance, *Fap*^−/−^ mice did not exhibit abnormalities of pancreatic histology, including β-cell and α-cell area, and liver morphology compared to *Fap*^+/+^ controls ([Figure S7](#appsec1){ref-type="sec"}). Taken together, these results demonstrate that whole body germline elimination of FAP does not impair glucose homeostasis, islet hormone responses, or the control of body weight and metabolism, in RC- or HFD-fed *Fap*^−/−^ mice.Figure 4**Male *Fap***^**−/−**^**mice fed a HFD develop obesity and insulin resistance similar to control mice.** Beginning at 12 weeks of age, male *Fap*^+/+^ and ^−/−^ mice were given chronic ad libitum access to 45% kcal fat HFD. Tests were conducted weekly, starting at 24 weeks of age. **A)** HFD induced weight gain. **B)** Body composition. **C)** Food intake. **D)** OGTT and AUC analysis. **E)** Plasma insulin during OGTT. **F)** Plasma glucagon during OGTT. **G)** IPGTT and AUC analysis. **H)** Plasma insulin during IPGTT. **I)** Plasma glucagon during IPGTT. **J)** ITT and AUC analysis. **K)** Fasting plasma insulin prior to ITT. **L)** Plasma glucagon during ITT. **M)** TG levels during LTT and AUC analysis. Data were analyzed using 2-way ANOVA or two-tailed *t*-test. \*P \< 0.05.Figure 4

3.5. Relative expression of mRNA transcripts encoding related members of the DASH enzyme family {#sec3.5}
-----------------------------------------------------------------------------------------------

To assess whether the normal metabolic phenotype in *Fap*^−/−^ mice might reflect compensatory upregulation of the expression of related DASH family genes, we examined mRNA levels of *Dpp4*, *Dpp8*, *Dpp9*, and the putative FAP substrate *Fgf21* in liver, epididymal white adipose tissue (eWAT), inguinal white adipose tissue (iWAT), pancreas, and muscle from *Fap*^+/+^ and *Fap*^−/−^ mice after RC or HFD feeding. No evidence for upregulation of these mRNA transcripts in *Fap*^−/−^ mouse tissues was observed ([Figure S8](#appsec1){ref-type="sec"}). Analysis of relative expression levels reported according to uncorrected CT values indicated the highest levels of *Fap* mRNA expression within muscle and adipose tissues ([Figure S9](#appsec1){ref-type="sec"}).

3.6. Pharmacological FAP inhibition does not lower glucose in *Fap*^*−/−*^ mice {#sec3.6}
-------------------------------------------------------------------------------

To reconcile the reduction of glucose excursion observed following acute inhibition of FAP activity using CPD60 with the normal glucose tolerance in *Fap*^−/−^ mice, we used *Fap*^−/−^ mice to assess the specificity of CPD60. Although glucose excursion was reduced in CPD60-treated *Fap*^+/+^ mice during an OGTT, no glucose-lowering effect of CPD60 was detected in *Fap*^−/−^ mice ([Figure 5](#fig5){ref-type="fig"}A, B) and plasma levels of insulin and glucagon were not different in *Fap*^+/+^ vs. *Fap*^−/−^ mice in the presence or absence of CPD60 ([Figure 5](#fig5){ref-type="fig"}C, D). Hence, CPD60 requires FAP to acutely improve oral glucose tolerance.Figure 5**Pharmacological FAP inhibition does not lower glucose in *Fap***^**−/−**^**mice.** Adult *Fap*^+/+^ and *Fap*^−/−^ mice were treated with oral CPD60 or vehicle 30 min prior to each test in a 2 treatment crossover study. **A)** OGTT with vehicle or CPD60 in *Fap*^+/+^ mice and AUC analysis. **B)** OGTT with vehicle or CPD60 in *Fap*^−/−^ mice and AUC analysis. **C)** Insulin levels during OGTT. **D)** Glucagon levels during OGTT. 2-way ANOVA revealed no significant differences in hormone response to drug within genotypes. AUC analyses were tested using paired *t*-tests. \*P \< 0.05.Figure 5

3.7. Talabostat inhibits DPP-4 enzymatic activity and requires *Dpp4* to improve glucose tolerance {#sec3.7}
--------------------------------------------------------------------------------------------------

The finding that complete genetic elimination of FAP activity produces no substantial metabolic phenotype contrasts with the metabolic benefits previously ascribed to pharmacological FAP inhibition with talabostat (Val-boroPro) [@bib22]. Talabostat has been reported to potentiate FGF-21 activity, through actions ascribed to enzymatic FAP inhibition [@bib22], [@bib33]; however, talabostat is first and foremost a DPP4 inhibitor and therefore also exerts anti-diabetic activity via inhibition of DPP-4 [@bib23], [@bib25], [@bib26], [@bib34], [@bib35]. To reconcile these findings, we compared the acute actions of talabostat in *Fgf21*^−/−^, *Dpp4*^−/−^, and *Fap*^−/−^ mice and their littermate controls. Notably, talabostat improved glucose tolerance and increased plasma insulin levels in *Fgf21*^−/−^ mice ([Figure 6](#fig6){ref-type="fig"}A--C). In contrast, talabostat was highly effective at lowing glucose excursions in *Dpp4*^+/+^ but not in *Dpp4*^−/−^ mice ([Figure 6](#fig6){ref-type="fig"}D, E), without further augmentation of plasma insulin levels ([Figure 6](#fig6){ref-type="fig"}F). Interestingly, talabostat acutely improved glucose homeostasis in both *Fap*^+/+^ and *Fap*^−/−^ mice, without further augmentation of insulin levels ([Figure 6](#fig6){ref-type="fig"}G--I). Consistent with these findings, talabostat potently inhibited plasma DPP-4 activity in all groups and had little effect on FAP activity at the dose used; in contrast CPD60 suppressed FAP, but not DPP-4 activity ([Figure 6](#fig6){ref-type="fig"}J--K). Furthermore, no genotype or drug-dependent changes in total immunoreactive FGF-21 levels were detected in the fasted state ([Figure 6](#fig6){ref-type="fig"}L). Taken together, these results indicate that germline genetic elimination of *Fap* in mice is not associated with improvements in glucose control or resistance to diet-induced obesity. Furthermore, the metabolic benefits ascribed to talabostat administration likely reflect actions predominantly arising from potent inhibition of DPP-4, and not FAP activity.Figure 6**Talabostat lowers glucose independently of FAP and FGF-21.** Adult *Fgf21*^+/+^ and *Fgf21*^−/−^, *Dpp4*^+/+^ and *Dpp4*^−/−^, and *Fap*^+/+^ and *Fap*^−/−^ mice were treated with either vehicle or talabostat (Val-boroPro) by oral gavage 30 min prior to an OGTT. **A, B)** 16-week old male *Fgf21*^+/+^ and *Fgf21*^−/−^ mice treated with talabostat prior to an OGTT, and AUC analyses. **C)** Insulin levels during OGTT in all treatment groups and *Fgf21* genotypes. **D, E)** 18-week old *Dpp4*^+/+^ and *Dpp4*^−/−^ mice treated with talabostat prior to an OGTT, and AUC analyses. **F)** Insulin levels during OGTT in all treatment groups and *Dpp4* genotypes. **G, H)** 30-week old male and female *Fap*^+/+^ and *Fap*^−/−^ mice treated with talabostat prior to an OGTT, and AUC analyses. **I)** Insulin levels during OGTT in all treatment groups and *Dpp4* genotypes. **J)** Plasma DPP-4 activity 45 min after treatment with CPD60 or talabostat in mice with different genotypes. **K)** Plasma FAP activity 45 min after CPD60 or talabostat administration. **L)** Plasma FGF-21 levels after an 18-hour fast in male and female *Fap*^+/+^, *Fap*^−/−^, and vehicle- or CPD60-treated C57BL6 mice. Due to the design of the crossover studies, data were analyzed using paired *t*-test. \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001, \*\*\*\*P \< 0.0001.Figure 6

4. Discussion {#sec4}
=============

Our current experiments directed at elucidating the metabolic importance of FAP were motivated by recent studies supporting a role for FAP in control of glycemia and body weight [@bib22], together with an extensive literature highlighting the metabolic importance of the structurally and functionally related DASH enzyme, DPP-4 [@bib7], [@bib9], [@bib10]. Notably, plasma levels of both DPP-4 and FAP activity are increased in human subjects with T2D [@bib36], [@bib37], consistent with the possibility that increased expression of one or both enzymes contributes to the development of dysglycemia via degradation of glucoregulatory substrates. Indeed, DPP-4 has been extensively validated, in studies ranging from mouse genetics to clinical trials using DPP-4 inhibitors, as an essential enzyme regulating glucose homeostasis and islet function [@bib7], [@bib9], [@bib10], [@bib11].

Several previous studies linking inhibition of FAP activity to reduction of glucose and body weight in mice [@bib22] employed talabostat, a non-selective FAP inhibitor, that also inhibits other members of the structurally related DASH enzyme family, especially DPP4 [@bib34]. Intriguingly, the favorable metabolic activity of talabostat, including reduction of glucose and body weight, and augmentation of circulating levels of FGF-21, was reported to be predominantly evident in mice with diet-induced obesity, and markedly attenuated in lean euglycemic mice [@bib22]. Here we demonstrate that acute reduction of FAP activity, using CPD60, a highly selective FAP inhibitor [@bib27], [@bib32], was associated with a modest but significant improvement in oral and intraperitoneal glucose tolerance without affecting insulin or glucagon levels. In contrast, complete elimination of FAP activity in *Fap*^−/−^ mice was not associated with changes in glucose tolerance, islet hormones, or insulin sensitivity, even under conditions of prolonged HFD-feeding. Hence, collectively, our data suggest that, in contrast to the favorable metabolic phenotype described for *Dpp4*^−/−^ mice [@bib11], genetic loss of *Fap* is not essential for control of metabolic homeostasis in mice.

One simple explanation for the favorable metabolic actions of talabostat in obese mice [@bib22], vs. the modest actions of the relatively FAP-selective CPD60, is the potent inhibition of DPP-4 activity by talabostat [@bib25]. Indeed, our current findings verify that talabostat at the dose previously utilized [@bib22] robustly reduces DPP-4 activity and not FAP activity, and fails to further improve glucose tolerance in *Dpp4*^−/−^ mice. Notably, DPP-4 and FAP are co-expressed on several cell types [@bib38], and have been shown to cleave an overlapping set of regulatory peptides, including neuropeptide Y (NPY), peptide YY, B-type natriuretic peptide and substance P [@bib15]. FAP and DPP-4 also physically interact to form a heteromeric complex that retains functional enzyme activity [@bib38], [@bib39]. Hence, it seems reasonable to explore the therapeutic potential of dual enzyme inhibitors for the treatment of metabolic disease, given the close inter-dependent structural and functional overlapping interactions demonstrated for FAP and DPP-4.

Enthusiasm for the exploration of single or dual FAP inhibitors as a therapeutic approach for treatment of metabolic disorders stems in part from the role of FAP in the cleavage and inactivation of FGF-21. Indeed, genetic ablation, immunodepletion, or pharmacological inhibition of FAP activity, with inhibitors such as CPD60, markedly inhibits the cleavage of human FGF-21 [@bib32], [@bib33]. Nevertheless, the importance and biological activity of N-terminally cleaved forms of FGF-21 and their relationship to relative levels of total circulating immunoreactive FGF-21 has not been extensively assessed in humans. Although mouse FAP is capable of cleaving human FGF-21 [@bib33], the extent to which mouse FGF-21 is cleaved and inactivated by mouse FAP is less certain. Mouse FGF-21 contains a Glu--Pro dipeptide at position 170--171 in place of the human Gly--Pro FAP cleavage sequence, which renders mouse FGF-21 relatively resistant to FAP cleavage at this site in the protein [@bib32], [@bib33]. We did not observe differences in plasma levels of total immunoreactive FGF-21, measured in the fasting state, nor in *Fgf2*1 mRNA in several tissues in RC- or HFD-fed *Fap*^−/−^ vs. *Fap*^+/+^ mice. Indeed endogenous plasma FGF-21 levels were previously reported to be similar in littermate control *Fap*^+/+^ vs. *Fap*^−/−^ mice [@bib32]. Although we demonstrate here that talabostat retained its acute glucoregulatory activity in *Fgf21*^−/−^ mice, a 7 day course of talabostat did not fully improve glucose tolerance, reduce body weight or adiposity in *Fgf21*^−/−^ mice, relative to its corresponding efficacy in *Fgf21*^+/+^ littermate controls [@bib22]. Moreover, plasma levels of FGF-21 were reported to be similar in *Fap*^+/+^ vs. *Fap*^−/−^ mice [@bib32]. Hence, the importance of murine FGF-21 for transducing the acute and chronic metabolic actions of single FAP or dual FAP/DPP-4 inhibitors requires further investigation.

Our studies of Fgf-21 expression did not reveal induction of *Fgf21* mRNA transcripts in liver, muscle, fat, or pancreas of 40 wk-old male mice after prolonged high fat feeding. In contrast, FGF-21 expression was induced in multiple tissues in high fat fed monkeys [@bib40], in mice fed a ketogenic diet [@bib41], and pancreatic [@bib42] and hepatic [@bib43] levels of *Fgf21* mRNA were upregulated in mice following high fat feeding. These differences in nutrient control of *Fgf21* expression may reflect species-specific differences and experimental conditions, including diets, genetic background, age, and sex of mice that differ in various studies across laboratories.

The generation and phenotypic characterization of *Fap*^−/−^ mice has been described over 15 years ago, with reports of normal growth and development in the setting of complete absence of Fap protein and enzyme activity [@bib44]. More recently, an independent line of *Fap*^−/−^ mice generated on the C57BL/6 background for studies of cancer biology was reported to exhibit normal levels of plasma glucose, pancreatic weight, and pancreatic histology, although dynamic metabolic testing was not reported [@bib45]. The findings reported here of normal glucose homeostasis and body weight in RC- and HFD-fed *Fap*^−/−^ mice strongly suggest that FAP is not essential for the adaptive metabolic response to energy excess in mice.

5. Conclusions and limitations {#sec5}
==============================

Our studies in mice have several caveats, limiting extrapolation to human biology. First, the mouse FAP protein differs structurally and functionally from human FAP [@bib19]. Although circulating FAP enzymatic activity is relatively higher in mouse vs. human plasma [@bib19], mouse FAP exhibited a lower catalytic activity, compared to human FAP, *ex vivo* [@bib31]. Furthermore, it is possible that additional species-specific differences in the structure of putative metabolically active FAP substrates, beyond FGF-21, may further complicate interpretation of FAP biology in mice vs. humans. Notably, commercially available assays for measurement of FGF-21 in mice do not allow reliable discrimination of cleaved vs. intact forms of FGF-21, precluding definitive ascertainment of whether FAP cleaves FGF-21 in the studies reported here. Additionally, we studied mice with complete elimination of *Fap* in all tissues, and developmental adaptations and compensation in response to global germline elimination of FAP may modify the biological phenotypes arising from loss of FAP in one or more tissues. Notably, acute transient FAP inhibition with CPD60, a short-acting FAP inhibitor, does improve oral and intraperitoneal glucose tolerance via currently unknown mechanisms, hence a role for more sustained pharmacological FAP inhibition as a therapeutic opportunity for metabolic disorders such as diabetes cannot be excluded by our data. Taken together, these findings have relevance for the design of preclinical experimental paradigms to assess the therapeutic potential of FAP in the control of metabolism and energy homeostasis.
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